<?xml version="1.0" encoding="UTF-8"?>
<p>The blockade of the JAK pathways leads to a wider suppression of cytokine-mediated responses. JAK 1 and 3 inhibition downregulates IFNÎ³, which has a role in viral clearance
 <sup>
  <xref rid="CIT0037" ref-type="bibr">37</xref>
 </sup> and has been associated with an increased risk for herpes-zoster infection.
 <sup>
  <xref rid="CIT0092" ref-type="bibr">92</xref>
 </sup> Conversely, JAK 2 inhibition has been proposed as a therapeutic strategy for COVID-19.
 <sup>
  <xref rid="CIT0093" ref-type="bibr">93</xref>
 </sup> No definitive conclusions on tofacitinib (JAK 1 and 3 inhibitor) can be drawn in respect to SARS-CoV-2: discontinuation is not currently recommended,
 <sup>
  <xref rid="CIT0079" ref-type="bibr">79</xref>
 </sup> but initiation in epidemic areas should be avoided, unless appropriate alternatives are not available.
 <sup>
  <xref rid="CIT0094" ref-type="bibr">94</xref>
 </sup>
</p>
